Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cefadroxil monohydrate

Executive Summary

International Trade Commission grants Bristol-Myers Squibb temporary relief Jan. 10 following a recent federal circuit court determination that the company's disputed '657 patent is "likely to be sustained" ("The Pink Sheet" Dec. 18, T&G-4). The ITC issued a cease and desist order prohibiting domestic marketing of the antibiotic by Biocraft, Kalipharma and Purepac unless a bond is posted for 68% of the "entered value of the imported articles," ITC said in a notice published in the Jan. 18 Federal Register. The commission also gave a temporary limited exclusion order prohibiting foreign manufacturers from importing the product without posting bond for 68% of its value. The orders will remain effective until the ITC reaches its final determination, due March 15.



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts